Antenatal Breastmilk Expression in Pregnant Women at High Risk of Preterm Birth
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorOdense University Hospital
About this trial
In this randomized controlled study, the investigators aim to examine if antenatal breastmilk expression (aBME) from week 28 in high-risk pregnancies is a safe and effective method to ensure early access to mother's own milk.
In addition, this study will analyze and compare colostrum from pregnancy with colostrum after birth, investigates women's confidence in breastfeeding and breastfeeding establishment as well as measures oxytocin levels during aBME and active labour with no aBME.
Eligibility criteria
Qualifiers
Pregnant women with a GA between 28 weeks and 0 days and 34 weeks and 0 days who are either diagnosed with preeclampsia or PPROM or have previously given birth before 34 weeks of gestation
Resident in the Region of Southern Denmark
Women speaking and understanding Danish or English
Planning to breastfeed their infants
Disqualifiers
HELLP or severe preeclampsia indicating expected induction of labour/caesarean section within a few days (According to national guidelines)
Chorioamnionitis indicating induction of labour/caesarean section within a few days
Women with a vaginal cerclage and PPROM
Women taking medications contraindicating breastfeeding
Trial design
Treatments tested in this trial
- Handstimulation of breast
Treatment groups
250 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Odense University Hospital
Lead sponsor
Aabenraa Hospital
Collaborator
Esbjerg Hospital - University Hospital of Southern Denmark
Collaborator
Kolding Sygehus
Collaborator
University of Aarhus
Collaborator
Source ClinicalTrials.gov